The Technical Analyst
Myovant Sciences Ltd [MYOV]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Myovant Sciences Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.04% $26.98
America/New_York / 9 mar 2023 @ 16:01
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 624.06 mill |
| EPS: | -1.920 |
| P/E: | -14.05 |
| Earnings Date: | Jul 25, 2023 |
| SharesOutstanding: | 97.26 mill |
| Avg Daily Volume: | 1.091 mill |
| RATING 2023-03-09 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.05 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.35x |
| Company: PE -14.05 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 26.92 - 27.04 ( +/- 0.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-10 | Valente Nancy | Sell | 3 673 | Common Shares |
| 2023-03-10 | Valente Nancy | Sell | 36 892 | Stock Options (Right to Buy) |
| 2023-03-10 | Potter Myrtle S | Sell | 3 673 | Common Shares |
| 2023-03-10 | Potter Myrtle S | Sell | 45 000 | Stock Options (Right to Buy) |
| 2023-03-10 | Potter Myrtle S | Sell | 58 608 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 71.96 |
| Last 100 transactions |
| Buy: 52 768 183 | Sell: 8 648 674 |
Forecast:
01:40 - $27.23
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $26.98 (-0.04% ) |
| Volume | 2.26 mill |
| Avg. Vol. | 1.091 mill |
| % of Avg. Vol | 206.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MYOV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MYOV
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Last 10 Buy Signals
Latest Press Releases
2023-11-11 11:11:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Myovant Sciences, Ltd. - Myov
New york , nov. 11, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of myovant sciences, ltd. ("myovant" or the "company") (nasdaq: myov).
2023-11-03 16:22:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Myovant Sciences, Ltd. - Myov
New york , nov. 3, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of myovant sciences, ltd. ("myovant" or the "company") (nasdaq: myov).
2023-10-25 14:54:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Myovant Sciences, Ltd. - Myov
New york , oct. 25, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of myovant sciences, ltd. ("myovant" or the "company") (nasdaq: myov).
2023-10-17 14:52:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Myovant Sciences, Ltd. - Myov
New york , oct. 17, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of myovant sciences, ltd. ("myovant" or the "company") (nasdaq: myov).
2023-10-09 17:40:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Myovant Sciences, Ltd. - Myov
New york , oct. 9, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of myovant sciences, ltd. ("myovant" or the "company") (nasdaq: myov).
Latest News
2023-01-26 18:48:23 - Zacks Investment Research
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-26 11:19:56 - Zacks Investment Research
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-24 23:29:02 - Pulse2
Why Sumitomo Pharma Is Buying Myovant Sciences (MYOV) For $2.9 Billion
Sumitovant Biopharma recently announced it is buying Myovant Sciences (MYOV) in a $2.9 billion deal. This is why.
2022-10-24 16:30:00 - GlobeNewsWire
Myovant Sciences Cancels Second Quarter Earnings Conference Call
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.
2022-10-24 11:23:36 - InvestorPlace
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don't already own. Furthermore, they raised their offer to make this purchase.
2022-10-24 09:36:00 - Benzinga
Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.
2022-10-24 08:12:07 - Market Watch
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.
2022-10-14 06:45:00 - GlobeNewsWire
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.
2022-10-07 18:44:58 - Seeking Alpha
Myovant Sciences: What The Sumitomo Offer Foretells
As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstanding shares at $22.75. However, Myovant's Board rejected the offer.
2022-10-04 14:34:38 - Seeking Alpha
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shares for $22.75 per share.